FDG PET of primary benign and malignant bone tumors: Standardized uptake value in 52 lesions

Radiology

Volumn 219, Issue 3, 2001, Pages 774-777

  Aoki, Jun ^a   Watanabe, Hideomi ^a   Shinozaki, Tetsuya ^a   Takagishi, Kenjl ^a   Ishijima, Hideyuki ^a   Oya, Nariyuki ^a   Sato, Noriko ^a   Inoue, Tomio ^a   Endo, Keigo ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Bone neoplasms, diagnosis, 40.31, 40.32; Bone neoplasms, PET, 40.12163; Bone neoplasms, radionuclide studies, 40.12163; Fluorine, radioactive

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; AGED; ARTICLE; BENIGN TUMOR; BONE TUMOR; CHONDROBLASTOMA; CHONDROSARCOMA; FEMALE; FIBROUS DYSPLASIA; GIANT CELL TUMOR; HISTIOCYTOSIS X; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; OSTEOSARCOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SARCOIDOSIS; SCHOOL CHILD;

EID: 0035008940     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiology.219.3.r01ma08774     Document Type: Article

References (26)

1. Strauss LG, Conti PS. The applications of PET in oncology. J Nucl Med 1991; 32:623-648.
2. Hoh CK, Schiepers C, Seltzer MA, et al. PET in oncology: will it replace the other modalities? Semin Nucl Med 1997; 27:94-106.
3. Brock CS, Meikle SR, Price P. Dose fluorine-18 fluorodeoxy glucose metabolic imaging of tumors benefit oncology? Eur J Nucl Med 1997; 24:691-705.
4. Kern KA, Brunetti A, Norton JA, et al. Metabolic imaging of human extremity musculo-skeletal tumors by PET. J Nucl Med 1988; 29:181-186.
5. Adler LP, Blair HF, Makley JT, et al. Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 1991; 32:1508-1512.
6. Griffeth LK, Dehdashti FD, McGire AH, et al. PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose. Radiology 1992; 182:185-194.
7. Dehdashti FD, Siegel GA, Griffeth LK, et al. Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-D-glucose. Radiology 1996; 200:24:1-247.
8. Kole AC, Nieweg OE, Hoekstra HJ, van Horn JR, Koops HS, Vaalburg W. Fluorine-18-fluorodeoxyglucose assessment of glucose metabolism in bone tumors. J Nucl Med 1998; 39:810-815.
9. Guhlmann A, Brechy-Krauss D, Suger G, et al. Chronic osteomyelitis: detection with FDG PET and correlation with histopathologic findings. Radiology 1998; 206:749-754.
10. Palmer WE, Rosenthal DI, Schoenberg OI, et al. Quantification of inflammation in the wrist with gadolinium-enhanced MR imaging and PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995; 196:647-655.
11. Hamacher K, Coenen HH, Stocklin G. Efficient stereospecific synthesis of non-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986; 27:235-238.
12. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 1993; 189:847-850.
13. Meikle SR, Bailey DL, Hooper PK, et al. Simultaneous emission and transmission measurement for attenuation correction in wholebody PET. J Nucl Med 1995; 36:1680-1688.
14. Inoue T, Kim EE, Komaki R, et al. Detecting recurrent or residual lung cancer with PET-FDG. J Nucl Med 1995; 36:788-793.
15. Johnston J. Giant cell tumor of bone: the role of the giant cell in orthopedic pathology. Orthop Clin North Am 1977; 8:751-770.
16. Ling L, Klein MJ, Sissons HA, Steiner GC, Winchester RJ. Expression of Ia and monocyte-macrophage lineage antigens in giant cell tumor of bone and related lesions. Arch Pathol Lab Med 1988; 112:65-69.
17. Meszaros K, Lang CH, Bagby GJ, Spitzer JJ. Contribution of different organs to increased glucose consumption after endotoxin administration. J Biol Chem 1987; 262:10965-10970.
18. Gamelli RL, Liu H, He L, Hofmann CA. Augmentation of glucose transporter-1 in macrophages following thermal injury and sepsis in mice. J Leukoc Biol 1996; 59:639-647.
19. Brudin LH, Valid SO, Rhodes CG, et al. Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med 1994; 21:297-305.
20. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33:1972-1980.
21. Brudin LH, Valid SO, Rhodes CG, et al. Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med 1994; 21:297-305.
22. Yamada Y, Uchida Y, Tatsumi K, et al. Fluorine-18-fluorodeoxyglucose and carbon-11-methionine evaluation of lymphadenopathy in sarcoidosis. J Nucl Med 1998; 39:1160-1166.
23. Cook GRC, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med 1996; 26:308-314.
24. Raisz LG, Rodan GA. Cellular basis for bone turnover. In: Avioli LV, Krane SM, eds. Metabolic bone disease and clinically related disorders. 2nd ed. Philadelphia, Pa: Saunders, 1990; 1-41.
25. Dahlin DC, Unni KK. Bone tumors: general aspects and data on 8,542 cases. 4th ed. Springfield, III: Thomas, 1986; 413-420.
26. Kubota K, Kubota R, Yamada S. FDG accumulation in tumor tissue (editorial). J Nucl Med 1993; 34:419-421.